Microdosing GLP-1 and Accutane: What Does It Mean—and Does It Work?

From Hollywood actors crediting it for their “flawless skin” to wellness influencers promising “effortless weight loss,” microdosing is having its moment. The term shows up across social media feeds and telehealth platforms alike.

But what does microdosing actually mean when it comes to prescription medications? Does it work—and is it safe?

In medical terms, microdosing generally refers to taking a dose lower than the lowest FDA-approved dose of a medication. It is not a formal clinical term, but it has gained popularity, particularly in conversations about isotretinoin (commonly known as Accutane) for acne and GLP-1 medications for weight loss.

“Microdosing is a term used to describe a dose below the lowest available dose approved by the FDA,” says Jorge Moreno, MD, a board-certified obesity medicine physician and assistant professor of medicine at Yale School of Medicine. “Although not a medical term, it has gained popularity largely because most GLP-1 medications are expensive, and many patients believe that a lower dose can mean fewer side effects.”

The approach, however, looks different depending on the medication—and the patient.

“We've been talking about low-dose regimens for a long time,” says Sara Perkins, MD, a board-certified dermatologist and clinician educator at Yale School of Medicine. “But this idea of microdosing has become much more part of the popular discourse—and I don't think that's entirely a bad thing.”

Isotretinoin is a powerful oral medication used to treat severe acne that has not responded to other therapies.

At standard doses—typically 0.5 to 1 milligram per kilogram of body weight per day—side effects can include dry skin and lips, hair thinning, joint pain, and increased sensitivity to the sun.

“Isotretinoin can have a lot of side effects that can make it difficult to tolerate,” Dr. Perkins says.

In dermatology, lower-dose regimens are not new. Some patients take 10 to 20 milligrams per day—lower than traditional weight-based dosing—with the goal of improving tolerability.

For isotretinoin, “Low-dose isotretinoin has fewer side effects,” Dr. Perkins says. “And as long as it's continued to completion, I don't think efficacy is really a question at this point either.”

However, lower dosing often means a longer treatment course. Instead of several months, treatment may extend to a year or more.

“If you're doing the treatment for 18 months, that really compounds,” she says. “Time away from work, time away from school—those are real costs that we don't talk about enough.”

In other words, for acne, lower dosing can be appropriate—but it requires commitment and close monitoring.

GLP-1 receptor agonists, such as semaglutide (sold under the brand name Ozempic or Wegovy) and tirzepatide (brand name Mounjaro or Zepbound), are medications originally developed for diabetes and now approved for chronic weight management at specific doses.

Clinical trials of FDA-approved GLP-1 medications have shown average weight loss of roughly 15 to 20 percent over about a year, depending on the drug and dose.

But Dr. Moreno emphasizes that “average” does not tell the full story.

“What we don't talk about is the differences in how individuals respond,” he says. “There are patients that didn't lose weight on these medications and there are patients that lost more than the average, and that is sometimes forgotten in a lot of trending media posts.”

Some patients respond strongly even at the lowest approved dose. Dr. Moreno refers to these patients as “super responders.”

“They're losing about one to two pounds per week, their blood pressure and cholesterol are all improving and their sleep apnea is getting better,” he says. “I don't see a reason for them to go up on the dose.”

That is different from microdosing below FDA-approved levels. For GLP-1s, there is limited evidence supporting doses lower than those studied in clinical trials.

“There is a suggestion that lower dosing may be helpful,” Dr. Moreno says, “but in these studies, we have not identified who those patients are, and we have not studied the dosing below the current FDA-labeled lower doses.”

Another concern involves compounded GLP-1 medications. Compounded drugs are custom-made by pharmacies and are not FDA-approved in the same way branded medications are.

During a nationwide shortage, the FDA temporarily allowed certain compounded versions of GLP-1 medications. That exemption has since expired. The FDA has stated that it cannot verify the quality, safety, or effectiveness of mass-marketed compounded GLP-1 products.

"The recipe for these medicines is not exactly the same as the FDA-branded medication," Dr. Moreno warns. "There is no standardization of the dosing, no standardization of safety—and there have been FDA reports of people ending up in the emergency room because of it."

Patients should know exactly what they are being prescribed and whether it is FDA-approved.

Not everyone who wants to microdose should. For acne, lower-dose isotretinoin may be appropriate for patients who:

• Are highly sensitive to side effects
• Require prolonged treatment
• Have difficulty tolerating standard doses

For GLP-1 medications, lower dosing within approved ranges may be reasonable if a patient is responding well. However, using doses below FDA-approved levels has not been well studied.

“People really concerned about the side effects of a medication, or who might need prolonged treatment, or who just kind of want to have an easier time tolerating the medicine,” Dr. Perkins says, “are often the best candidates for a lower dose.”

But any dose adjustment should be supervised by a licensed physician.

Yale Medicine physicians recommend the following:

• Confirm the indication: GLP-1 medications are approved for specific body mass index (BMI) thresholds and medical conditions. A lower dose is not a workaround if you do not meet criteria.
• Understand what you are taking: Ask whether the medication is FDA-approved or compounded.
• Expect close monitoring: Both isotretinoin and GLP-1 medications require medical follow-up.
• Be cautious about telehealth promises: If a platform promises “effortless” results at very low doses, ask questions.
• Seek specialty care when appropriate: Dermatologists and obesity medicine physicians are trained to individualize treatment safely.

“There are going to be patients who need a more individualized and nuanced approach,” Dr. Perkins says. “And that is hard to get from an algorithm.”

“Whoever is prescribing your medication should be licensed, knowledgeable, and in close contact with you,” Dr. Moreno says. “Seek out professionals and be cautious. There are options—and microdosing should not be the first one you reach for.”

If you are considering isotretinoin for acne or a GLP-1 medication for weight loss, start by discussing your goals, medical history, and concerns about side effects with your doctor.

In some cases, a lower-dose approach may be appropriate. In others, it may not provide the benefits you are hoping for.

Microdosing is not a shortcut. It is a dosing strategy that must be individualized—and guided by evidence, safety, and careful follow-up.